Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference

ROCKVILLE, Md., Jan. 2, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steven Shallcross, Interim CEO & CFO, is scheduled to present at the Biotech Showcase 2018 Conference next week in San Francisco, as follows:

Date: Tuesday, January 9, 2018
Time: 11:00 a.m. (PT) / 2:00 p.m. (ET)
Location: Hilton San Francisco Union Square, San Francisco, CA

Synthetic Biologics, Inc. (PRNewsFoto/Synthetic Biologics, Inc.)

A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the internet at After the presentation, a replay will be archived and accessible for 90 days at the same website.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company’s lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics’ website at


Cision View original content with multimedia:

SOURCE Synthetic Biologics, Inc.